Vimovo and Pregnancy
The U.S. FDA lists Vimovo (naproxen/esomeprazole magnesium) as a pregnancy Category C medication when used during the first 29 weeks of pregnancy, and as a Category D drug during week 30 and beyond. This means that the drug may not be safe for pregnant women, as it might increase the risk for problems like miscarriages and heart or kidney problems in the fetus.
Can Pregnant Women Take Vimovo?Vimovo™ (naproxen/esomeprazole magnesium) is a prescription medication. It contains naproxen, which is a nonsteroidal anti-inflammatory drug (NSAID), and esomeprazole, which is a proton pump inhibitor (PPI). NSAIDs and esomeprazole magnesium may present some risks to the fetus when taken during pregnancy, although the full risks are currently unknown.
The U.S. Food and Drug Administration (FDA) uses a pregnancy category system to classify the possible risks to a fetus when a specific medicine is taken during pregnancy. Vimovo is classified as a pregnancy Category C medication when used up to week 30 of pregnancy, and as a pregnancy Category D medication when used during week 30 of pregnancy or beyond.
Pregnancy Category C is given to medicines that have not been studied in pregnant humans, but do appear to cause harm to the fetus in animal studies. Also, medicines that have not been studied in any pregnant women or animals are automatically given a pregnancy Category C rating.
Pregnancy Category D is a classification given to medicines that have been shown to present a risk to the fetus in studies of pregnant women, but may still offer benefits that outweigh the risks the drug presents. A pregnancy Category D medicine may still be given to a pregnant woman if the healthcare provider believes that the benefits to the woman outweigh the possible risks to the unborn child.